HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Current approach to the treatment of polymyositis and dermatomyositis.

Abstract
Although corticosteroids remain the mainstay of treatment for the inflammatory myopathies, their use is complicated by many side effects. Other immunosuppressive agents, alone or in combination, are being increasingly used for patients with other severe disease or treatment-related complications. Pulmonary disease remains a serious source of morbidity and mortality in myositis patients. Cyclophosphamide, cyclosporine, and tacrolimus are efficacious in patients with interstitial lung disease. Intravenous immunoglobulin is not only effective for the cutaneous complications of dermatomyositis but has been helpful in other extramuscular manifestations.
AuthorsC V Oddis
JournalCurrent opinion in rheumatology (Curr Opin Rheumatol) Vol. 12 Issue 6 Pg. 492-7 (Nov 2000) ISSN: 1040-8711 [Print] United States
PMID11092197 (Publication Type: Journal Article, Review)
Chemical References
  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Cyclosporine
Topics
  • Adrenal Cortex Hormones (therapeutic use)
  • Cyclosporine (therapeutic use)
  • Dermatomyositis (immunology, therapy)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Lung Diseases (immunology, therapy)
  • Polymyositis (immunology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: